CRH and Parkinson disease: The similar differences observed for CSF DDC, FCER2, CRH, and MMP3 also in the PD data sets call for additional studies that evaluate the performance of these markers in other α-synucleinopathies (e.g., multiple system atrophy), other dementia types with motor dysfunctions (e.g., progressive supranuclear palsy, corticobasal degeneration) or other conditions with dopamine deficiency (e.g., psychiatry disorders).